Karin Cohén's Contact Details

Karin Cohén's Company Details

Swedish Orphan Biovitrum AB (Sobi)

23a Tomtebodavägen, Stockholm 112 76, SE • 1940 Employees
Major Drugs

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. We have a diversified and growth-oriented commercial product portfolio. Key therapeutic areas are Inflammation and Genetics & Metabolism. Our late stage pipeline includes three phase III programs with substantial potential. We have world-class capabilities in protein biochemistry and biologics manufacturing development - validated by leading industry partners. Our sales and marketing organization covers about 20 countries in Europe and a subsidiary in the US. We are also represented through partners in in the Middle East, Australia and New Zealand. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.